• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints > Bringing Chagas disease care closer to people who need it > Page 2

Bringing Chagas disease care closer to people who need it

Home > Viewpoints > Bringing Chagas disease care closer to people who need it > Page 2

Bringing Chagas disease care closer to people who need it

14 Apr 2023

By Dr Sergio Sosa-Estani, DNDi Latin America Director

Since the 1990s, we have seen progress in the control of Chagas disease transmission in Latin America. Despite this progress, we still face great challenges to bring diagnosis and treatment to populations affected by this deadly and very neglected disease: less than 10% of the 75 million people at risk of contracting Chagas are tested in the Americas, and only 1% have access to treatment each year, leaving millions behind. 

Sergio Sosa Estani

On this World Chagas Day, we at DNDi are underscoring the calls to action by the scientific community and patients’ associations through the Santa Cruz Letter issued in 2018, and the Bogotá Manifesto issued in 2022. Among the priority recommendations we highlight: improving access to diagnostics and treatments; increasing investment in research and development to obtain new diagnostic tools and simpler, safer treatments; improving disease surveillance and control as well as amplifying compulsory notification; and boosting support for the outreach and participation of affected people and their associations.  

To achieve these priorities, it is imperative to bring Chagas care closer to where people live. Initiatives promoted by the Pan American Health Organization and the World Health Organization with control programmes in endemic countries have shown that we must concentrate at the primary health care level. It is in primary health care that it is feasible to provide care to eight out of ten Chagas patients, in their own communities, with a timely and effective ’test and treat’ approach.  

In our twenty years working to improve research and access to treatment for Chagas, DNDi has tirelessly advocated for the rights of patients to be treated where they are, lessening the burden on individuals, their families, their communities, and the health system as a whole. A patient-centered approach at the primary health care level increases access and adherence to treatment. It would bring hope for people with a disease that, despite a few achievements, remains a silent killer in Latin America. 

Photo credit: Ana Ferreira-DNDi

Chagas disease Latin America

Read, watch, share

Loading...
Stories
14 Apr 2025

DNDi supporting a pioneering project that integrates Indigenous knowledge in the treatment of Chagas

Veja Saúde
Viewpoints
9 Apr 2025

Como acabar de vez com as doenças negligenciadas?

Veja Saúde
C&EN logo
Viewpoints
3 Apr 2025

Opinion: How patents can serve the common good

Chemical & Engineering News
TRT Afrika logo
Viewpoints
3 Apr 2025

Africa’s greatest health challenges won’t be solved without female scientists

TRT Afrika
News
3 Apr 2025

DNDi looking for a new Patient Representative to join its Board of Directors

Drug Discovery Explained: Episode 3 What is lead optimization?
Stories
26 Mar 2025

Drug discovery explained: What is lead optimization?

Lab activities
Press releases
18 Mar 2025

DNDi welcomes GHIT support for new collaboration with Shionogi to identify novel drug candidates for neglected Chagas disease

Nature India Logo
Viewpoints
8 Mar 2025

Women are poorly represented in clinical trials. That’s problematic

Nature India
VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License